Audit: QRS - CoQ10 for Health & Longevity
Audit conducted on 24/08/2026 04:21 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to the ER: protocol cells (ER 379, 389, 393), time-to-effect (ER 438, 408, 383), all 9 monitoring rows and the cadence (ER 468–480), 5 contraindications (ER 353–357), 10 interactions (ER 329–349), benefit and risk tiers (ER 155–247, 271–309), qualitative list (ER 484–489), At-A-Glance (ER 515–519). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The At-A-Glance carries the ER’s own hedges verbatim in substance: “Benefits concentrate in people who start out depleted or unwell” and “In people already well, the same doses move very little” mirror ER 517; “product quality is the weak link” mirrors ER 519. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy before 20 weeks and breastfeeding stay absolute contraindications (ER 353); warfarin in general stays a Key Interaction (ER 329) while only the unstable-INR subgroup is escalated to Contraindications, exactly as the ER splits them (ER 354). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Nothing from ER Benefit-Modifying Factors (ER 250–264) or Risk-Modifying Factors (ER 312–324) appears in the gates or the risk card; both gates draw only on ER Key Interactions & Contraindications (ER 327–357), and the risk tiers only on ER Potential Risks & Side Effects (ER 267–309). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The sheet carries no PMIDs, no NCT numbers, no author names and no brand names; the ER’s Pharma Nord, Kaneka, Langsjoen and Life Extension attributions (ER 159, 191, 283, 387) are all absent. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution of any kind appears in any populated span. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The sheet reproduces the ER’s measured, depletion-conditional framing — benefit where baseline is low, little movement where it is not (ER 517) — without adding enthusiasm. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets (plasma CoQ10, INR, NT-proBNP) and explicit decision gates supply what is needed to act, while the limits of the evidence are stated plainly in the At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Every gate, benefit, risk and monitoring entry is a noun phrase or a descriptive statement; no prescriptive verb appears anywhere. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Doses and thresholds are stated as what the trials and the ER’s protocol used, not as instructions; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should”, “must” or “we suggest” in any populated span. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns and no imperatives; verified by a full-file search for “you”/”your”. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | The At-A-Glance uses “energy machinery”, “blood sugar or blood fats”, “tiredness”; the monitoring rows reuse the ER’s own already-expanded labels (“High-sensitivity C-reactive protein”, “Low-density lipoprotein cholesterol”), and the residual short forms (HbA1c, INR, ALT, NT-proBNP) are the ER table’s verbatim biomarker names required by 4.2. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate item, benefit and risk entry is a single condensed phrase; continuous prose is confined to the At-A-Glance and the cadence line. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed across all populated spans. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-optimal targets are used rather than conventional laboratory cut-offs (plasma CoQ10 1.0–2.5 µg/mL against the ER’s note that conventional labs quote 0.4–1.6; hs-CRP <1.0 mg/L; HbA1c 4.8–5.4%; ALT 10–26/10–33 U/L). |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing above 200 mg, dosing with the heaviest fatty meal, a last dose before 16:00 and a nine-marker baseline panel all presume a reader willing to accept inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nothing is simplified to a single “take one capsule” instruction; the sheet retains the absorption, timing and level-testing conditions that determine whether the compound does anything. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance states outright that benefits concentrate in the depleted or unwell and that “in people already well, the same doses move very little” — the ER’s central caveat for an optimising, largely healthy readership (ER 517). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur anywhere in the file; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register is used throughout the gates, tiers and monitoring table (“anthracycline chemotherapy”, “Child-Pugh Class C”, “gastrointestinal intolerance”, “sleep onset latency”); the plainer wording is confined to the At-A-Glance, where 7.4 mandates it and where it reproduces the ER Conclusion’s own vocabulary (ER 515–519). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All match the template character for character: “Protocol” (446), “Time to effect” (492), “Benefits” (541), “Risk & Side Effects” (616), “Monitoring” (641), “Qualitative Assessment” (786), “Contraindications” (576), “Key Interactions” (591), the four tier labels (545, 552, 558, 566 and 619, 622, 626, 632) and “Marker”/”Target”/”Why” (645–647). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | A diff of the extracted variable names against core/qrs/QRS.html shows all 34 template variables present, with only the expected repeat expansions of marker_#_* into nine rows and qualitative_item_# into six items added. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans website="evidence_review" (423), website="audit" (426) and website="full_review" (440) are byte-identical to the template, as are the surrounding markup, style block and footer disclaimer. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that maps onto the QRS is empty — Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol and Monitoring Protocol are all fully populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cells reuse the ER’s bold labels verbatim: “Standard maintenance dose” (ER 379), “Best time of day” (ER 389), “Single versus split dosing” (ER 393); the nine monitoring row labels reuse the ER table’s Biomarker column verbatim (ER 472–480). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No protocol or monitoring label is shortened or reworded; the three time-to-effect labels describe outcomes for which the ER supplies no bold label of its own (ER 438), so nothing existing is displaced. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji occurs in the file; the ER’s tier emoji and its “⚠️ Conflicted” markers are dropped in favour of the template’s CSS palettes and bold tier labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every entry is condensed to a single phrase and the template’s one-page machinery (A4 @page rule, 8–11pt scale, two-column gates) is intact; nine monitoring rows and six qualitative items sit inside the range the completeness items 8.2, 9.2, 14.2 and 15.2 force. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the lead-in text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is a single HTML comment outside <html>; no filename, prompt version, creation timestamp or creator nickname is echoed in the header, footer or any card. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Every value is a single trimmed token or phrase; duration: "00:03" is the only quoted value and is quoted because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: coq10_2026-0824-0011_Opus_ER.md, matching the source ER’s own filename field (ER 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0824-0414, in the required YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — one word, no version and no qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: coq10_2026-0824-0011_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys: no stray whitespace, and the only quoting is the colon-bearing duration value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: CoQ10 for Health & Longevity - Quick Reference Sheet, built from the ER’s canonical_topic (ER 8) with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: CoQ10 for Health & Longevity, identical to the ER’s canonical_topic with the ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/24/2026, the MM/DD/YYYY rendering of qrs_creation_date: 2026-0824-0414. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching qrs_creator_ai_fullname on line 8. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template’s subline; the ER’s “Also known as” list (ER 30) and its alternate_names frontmatter are not surfaced, and no badge, audit date or variant marker is present. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | All four clauses map onto the ER Conclusion: endogenous synthesis and its decline with age and statins (ER 515), benefit concentrated in the depleted or unwell with the named conditions (ER 517), little movement in the already-well (ER 517), tolerability and product quality as the practical failure point (ER 519). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words (lines 434–438). |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to its own ER sentence at ER 515, 517 and 519; no claim is aggregated from unrelated passages. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “Energy machinery” for mitochondrial bioenergetics, “cholesterol-lowering medication” for statins, “disturbed blood sugar or blood fats” for dyslipidaemia and metabolic syndrome, “tiredness” for fatigue, “fertility treatment” for assisted reproduction; the only short form is the intervention’s own name, which the title already carries. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, participant count or p-value appears; the ER’s Q-SYMBIO-style event trial and Swedish selenium trial (ER 159, 191) are not named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No hazard ratio, odds ratio, mmHg figure or confidence interval appears; “move very little” replaces the ER’s numeric magnitudes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items trace to the “Populations who should avoid CoQ10” list inside that ER section (ER 351–357). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-list entries are present, none added: pregnancy/breastfeeding, unstable INR on warfarin, active anthracycline or curative-intent radiotherapy, Child-Pugh C or biliary obstruction, and pre-surgical anticoagulant window. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements inside the stop_items span, lines 579–586. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationales are all stripped: “— supplementation has been studied only from 20 weeks onward, and lactation data are absent” (ER 353), “, in whom absorption and clearance are both unpredictable” (ER 356) and “, given the unresolved INR signal” (ER 357). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “before 20 weeks’ gestation”, “(typically 2.0–3.0)”, “until the course is complete”, “Child-Pugh Class C” and “within 14 days of elective surgery” are all carried; only “their target range” is trimmed to “target”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses anywhere in Key Interactions & Contraindications. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five populations that should avoid the compound (ER 351–357), and the gate is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items trace to the interaction bullets at ER 329–349. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten of the ER’s eleven interaction bullets appear; the anthracycline chemotherapy and radiotherapy bullet (ER 337) is correctly excluded because it already sits in the Contraindications gate (ER 355). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements inside the caution_items span, lines 594–606. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is a bare noun phrase; every “Caution/Monitor” verdict, mechanism sentence and mitigation instruction is stripped (ER 329–349), as is the em-dash gloss “— tablets that make the pancreas release more insulin” (ER 333). |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The named example drugs are all carried: amlodipine/lisinopril/losartan/hydrochlorothiazide, glimepiride/gliclazide, atorvastatin/rosuvastatin/simvastatin, omeprazole, and the additive-supplement list omega-3/magnesium/garlic extract/beetroot or dietary nitrate/hibiscus/berberine (ER 331–347). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in Key Interactions & Contraindications. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eleven interactions (ER 329–349), and the gate is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to ER Therapeutic Protocol (ER 377–403), specifically the bullets at ER 379, 389 and 393. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and dose-splitting are the three decisions that apply to every user; the ER’s condition-specific regimens (heart failure ER 381, migraine ER 383) and the two contested philosophies (ER 385, 387) are narrower and are correctly left out. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies thirteen protocol bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine spans populated: “100–200 mg daily” with the ubiquinone/ubiquinol and no-benefit-above note (ER 379); “With the heaviest fatty meal” with the before-16:00 and split-meal note (ER 389); “Split above 200 mg” with the saturable-absorption rationale (ER 393). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Cardiovascular events, blood pressure and fatigue, and migraine prophylaxis are exactly the windows the ER states at ER 438, corroborated at ER 391 and 408. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Cardiovascular events lead because the ER’s largest magnitude is there (death 18% → 10%, ER 161); blood pressure and fatigue follow as the ER’s second High-tier benefit (ER 167); migraine, the smaller burden effect (ER 173), comes last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “1–2 years” with the continuous-use note (ER 438, 408); “4–12 weeks” with the one-week plasma steady state (ER 438, 391); “8–12 weeks” with the ER’s reason that shorter prevention trials are uninformative (ER 383). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data at ER 438, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers map one-to-one onto the ER headings at ER 155–247. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated, lines 543–569. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of the ER’s own benefit headings; none of the Magnitude figures at ER 161, 167, 173, 179, 185, 193, 199, 207, 213, 219, 225, 231, 237 is carried over, and the ER’s “⚠️ Conflicted” markers and Net-reading sentences are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span; the ER’s glosses such as “(abnormal blood fats)” and “(egg cells)” (ER 165, 183) are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four benefit tiers, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers map one-to-one onto the ER headings at ER 271–309. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated, lines 618–635. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier reproduces only the ER’s risk headings; the risk ratios, event counts and dose thresholds at ER 277, 285, 293 and 299 are all dropped, as is the Kaneka funding disclosure at ER 283. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span; the ER’s glosses “(upper abdominal)” and “(international normalised ratio, a standard clotting measure)” (ER 275, 291) are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four risk tiers, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table and the cadence line trace to ER Monitoring Protocol & Defining Success (ER 466–480). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine rows of the ER biomarker table are present with names, targets and rationales carried verbatim: Plasma CoQ10, Seated blood pressure, High-sensitivity C-reactive protein, Low-density lipoprotein cholesterol, HbA1c, INR, NT-proBNP, Serum selenium and ALT (ER 472–480). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 777–779 condense the ER’s cadence paragraph (ER 468): baseline, plasma CoQ10 and blood pressure at 8–12 weeks, INR at 2 and 4 weeks in warfarin users, then annually or every 6 months on dose or statin change. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items trace to the qualitative-marker list in ER Monitoring Protocol & Defining Success (ER 484–489). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER entries appear verbatim and none is added: daytime energy and afternoon slump, migraine or headache days, statin-related muscle symptoms, exercise tolerance, sleep onset latency and night waking, cognitive clarity and word-finding. |
Issues 24/08/2026 04:21
Pass rate 100.00%. No issues found.